Pseudovirus News and Research

RSS

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New research suggests SARS-CoV-2 spike protein substitution mutations can create a replication-defective viral particle that makes the virus resistant to vaccine-induced antibodies.

23 Sep 2021

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Researchers from the Broad Institute of MIT and Harvard have created a cell-free nanobody engineering platform that can produce antibodies effectively and quickly.

21 Sep 2021

Role of extracellular vesicles embedded with engineered ACE2 in the neutralization of the SARS-CoV-2 pseudovirus

Researchers discuss the preparation and characterization of EVs-ACE2, along with the production and characterization of SARS-CoV-2 S-pseudovirus.

20 Sep 2021

Research on SARS-CoV-2 and dendritic cells may explain why virus is so virulent

In a recent study released on the bioRxiv* preprint server, the researchers suggest that an aberrant inflammatory reaction associated with COVID-19 could be a result of escape from direct sensing by toll-like receptors (TLRs). Moreover, the researchers indicate that this phenomenon might underlie the lack of efficient immunity to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) early during infection.

20 Sep 2021

Study looks at exposure to different SARS-CoV-2 variants and immune response

Researchers compared the responses against several SARS-CoV-2 VoCs in sera from individuals exposed to variant infection, vaccination, or both.

15 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans

Scientists were inspired by the robust serum nAb responses in people who recovered from natural SARS-CoV-2 infection and were later vaccinated using mRNA vaccine. They isolated and characterized bnAbs from two COVID-19 convalescent donors who were recently vaccinated. These isolated bnAbs were found to be highly potent against sarbecoviruses. This research is available on the bioRxiv* preprint server.

13 Sep 2021

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

A group of researchers analyzed the B cell response to SARS-CoV-2 in unexposed individuals.

10 Sep 2021

Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals.

8 Sep 2021

The role of nanobodies in capturing and containing SARS-CoV-2

Scientists have repurposed the Nb Ty1 for the detection and neutralization of SARS-CoV-2.

8 Sep 2021

An assessment of post-vaccination immune response to SARS-CoV-2 Delta in elderly and health care workers

A new cohort study comparing immune responses among vaccinated elderly persons and healthcare workers has been conducted.

2 Sep 2021

J&J COVID-19 booster shot produces robust antibody response

The study showed neutralizing antibody responses produced by the Johnson & Johnson–Janssen vaccine was robust and stable eight months after immunization.

31 Aug 2021

Next-gen COVID vaccine to make persistent neutralizing antibodies

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. The findings from this study are published on the bioRxiv* preprint server while awaiting peer review.

30 Aug 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

Scientists assess SARS-CoV-2 mutants in ferret hosts

In a paper recently uploaded to the preprint server bioRxiv* by the cause of SARS-CoV-2 mutations observed in mink and ferrets is investigated, and the danger posed by such mutations to humans assessed.

26 Aug 2021

SARS-CoV-2 Delta likely to acquire resistance to wild-type spike vaccines

A new study published on the preprint server bioRxiv* explores the mechanism of the Delta variant's high infectivity and suggests a plausible pathway by which the Delta variant could escape from vaccine-induced immunity.

24 Aug 2021

Small study suggests a mix-and-match COVID-19 booster produces robust antibody levels

In a small study published in the medRxiv* preprint server, people given a booster Johnson & Johnson COVID-19 shot showed elevated and robust antibody levels.

19 Aug 2021

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

Pseudovirus News and Research

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New cell-free antibody generation platform successfully creates neutralizing antibodies effective against SARS-CoV-2

Role of extracellular vesicles embedded with engineered ACE2 in the neutralization of the SARS-CoV-2 pseudovirus

Research on SARS-CoV-2 and dendritic cells may explain why virus is so virulent

Study looks at exposure to different SARS-CoV-2 variants and immune response

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

Discovery of diverse sarbecovirus broadly neutralizing antibodies from SARS-CoV-2 “infected-vaccinated” humans

No evidence of pre-existing antibody and B cell immunity against SARS-CoV-2 in unexposed adults

Mu SARS-CoV-2 variant highly resistant to neutralization by convalescent and vaccinated sera

The role of nanobodies in capturing and containing SARS-CoV-2

An assessment of post-vaccination immune response to SARS-CoV-2 Delta in elderly and health care workers

J&J COVID-19 booster shot produces robust antibody response

Next-gen COVID vaccine to make persistent neutralizing antibodies

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

Scientists assess SARS-CoV-2 mutants in ferret hosts

SARS-CoV-2 Delta likely to acquire resistance to wild-type spike vaccines

Small study suggests a mix-and-match COVID-19 booster produces robust antibody levels

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News